The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Open accessAbstract
BACKGROUND: Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy. METHODS: We used immunohistochemical analysis to determine the expression of the excision repair cross-complementation group 1 (ERCC1) protein in operative specimens of non-small-cell lung cancer. The patients had been enrolled in the International Adjuvant Lung Cancer Trial, thereby allowing a comparison of the effect of adjuvant cisplatin-based chemotherapy on survival, according to ERCC1 expression. Overall survival was analyzed with a Cox model adjusted for clinical and pathological factors. RESULTS: Among 761 tumors, ERCC1 expression was positive in 335 (44%) and negative in 426 (56%). A benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of ERCC1 (test for interaction, P=0.009). Adjuvant chemotherapy, as compared with observation, significantly prolonged survival among patients with ERCC1-negative tumors (adjusted hazard ratio for death, 0.65; 95% confidence interval [CI], 0.50 to 0.86; P=0.002) but not among patients with ERCC1-positive tumors (adjusted hazard ratio for death, 1.14; 95% CI, 0.84 to 1.55; P=0.40). Among patients who did not receive adjuvant chemotherapy, those with ERCC1-positive tumors survived longer than those with ERCC1-negative tumors (adjusted hazard ratio for death, 0.66; 95% CI, 0.49 to 0.90; P=0.009). CONCLUSIONS: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Mechanisms of DNA Excision Repair
Sancar, A. (1994) · Science · doi:10.1126/science.7801120 · Cited by 555
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505
Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 492
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Silva, I. U. D., McHugh, P. J., Clingen, P. H., & Hartley, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.21.7980-7990.2000 · Cited by 441
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., & Green, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7019 · Cited by 380
Reaction Mechanism of Human DNA Repair Excision Nuclease
Mu, D., Hsu, D. S., & Sancar, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8285 · Cited by 374
Repair of Cisplatin−DNA Adducts by the Mammalian Excision Nuclease
Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A., & Lippard, S. J. (1996) · Biochemistry · doi:10.1021/bi960453+ · Cited by 333
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D. S., Wain, J. C., Lynch, T. J., Su, L., & Christiani, D. C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0247 · Cited by 291
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005) · Chest · doi:10.1378/chest.127.3.978 · Cited by 277
Viguier, J., Boige, V., Miquel, C., Pocard, M., Giraudeau, B., Sabourin, J.-C., Ducreux, M., Sarasin, A., & Praz, F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2216 · Cited by 226
DNA repair and cisplatin resistance in non-small-cell lung cancer
Rosell, R., Lord, R. V. N., Taron, M., & Reguart, N. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00224-6 · Cited by 178
Association of an ERCC1 polymorphism with adult-onset glioma.
Chen, P., Wiencke, J. K., Aldape, K., Kesler-Diaz, A., Miike, R., Kelsey, K. T., Lee, M., Liu, J., & Wrensch, M. (2000) · PubMed · Cited by 177
Reardon, J. T., Mu, D., & Sancar, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19451 · Cited by 161
Joshi, M.-B. M., Shirota, Y., Danenberg, K. D., Conlon, D. H., Salonga, D. S., Herndon, J. E., Danenberg, P. V., & Harpole, D. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1387 · Cited by 138
Sargent, R. G., Meservy, J. L., Perkins, B. D., Kilburn, A. E., Intody, Z., Adair, G. M., Nairn, R. S., & Wilson, J. H. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.19.3771 · Cited by 128
Warnecke‐Eberz, U., Metzger, R., Miyazono, F., Baldus, S. E., Neiß, S., Brabender, J., Schaefer, H., Doerfler, W., Bollschweiler, E., Dienes, H. P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0079 · Cited by 118
Sturgis, E. M., Dahlstrom, K. R., Spitz, M. R., & Wei, Q. (2002) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.128.9.1084 · Cited by 113
Wachters, F. M., Wong, L. S. M., Timens, W., Kampinga, H. H., & Groen, H. J. M. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.06.013 · Cited by 88
Handra‐Luca, A., Bilal, H., Bertrand, J.-C., & Fouret, P. J. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63455-4 · Cited by 83
Self-citationLanger, R., Specht, K., Becker, K., Ewald, P., Bekesch, M., Sarbia, M., Busch, R., Feith, M., Stein, H. J., Siewert, J.-R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0042 · Cited by 70
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationDrug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Metadata
- Authors
- Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., Stahel, R., Sabatier, L., Pignon, J.-P., Tursz, T., Le Chevalier, T., & Soria, J.-C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 983-991
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2004718750
- Cited by
- 1,727
- References
- 31
- FWCI
- 105.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.